U.S. Markets close in 3 hrs 46 mins
  • S&P 500

    3,913.45
    +1.71 (+0.04%)
     
  • Dow 30

    31,521.19
    +20.51 (+0.07%)
     
  • Nasdaq

    11,569.71
    -37.91 (-0.33%)
     
  • Russell 2000

    1,777.45
    +11.72 (+0.66%)
     
  • Crude Oil

    109.17
    +1.55 (+1.44%)
     
  • Gold

    1,827.60
    -2.70 (-0.15%)
     
  • Silver

    21.30
    +0.17 (+0.83%)
     
  • EUR/USD

    1.0604
    +0.0046 (+0.4348%)
     
  • 10-Yr Bond

    3.1870
    +0.0620 (+1.98%)
     
  • Vix

    27.46
    +0.23 (+0.84%)
     
  • GBP/USD

    1.2298
    +0.0028 (+0.2312%)
     
  • USD/JPY

    135.2290
    +0.0590 (+0.0437%)
     
  • BTC-USD

    20,717.28
    -601.12 (-2.82%)
     
  • CMC Crypto 200

    451.50
    -10.29 (-2.23%)
     
  • FTSE 100

    7,258.32
    +49.51 (+0.69%)
     
  • Nikkei 225

    26,871.27
    +379.30 (+1.43%)
     

Valneva announces resumption of trading of its ordinary shares on Euronext Paris

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
VALNEVA
VALNEVA

Saint-Herblain (France), June 23, 2022Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces the resumption of trading of its ordinary shares on the regulated market of Euronext in Paris, starting at 4:30pm CEST today.

At the request of the Company, trading of Valneva’s ordinary shares was suspended on June 23, 2022 from 9:00 AM CEST to allow for the publication of a press release by the European Medicines Agency regarding the Committee for Medicinal Products for Human Use (CHMP) opinion on marketing authorization in Europe for Valneva’s COVID-19 vaccine candidate, VLA2001.

About Valneva SE
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.

Investor & Media Contacts
Laëtitia Bachelot-Fontaine
VP Global Communications & European Investor Relations
M +33 (0)6 4516 7099
laetitia.bachelot-fontaine@valneva.com



Joshua Drumm, Ph.D.
VP Global Investor Relations
M +001 917 815 4520
joshua.drumm@valneva.com

Attachment